Evaluate the Safety of BEL-X-HG in Advanced Cancer Patients
A Phase I, Open-Label, Dose Escalation and Extension Study to Evaluate the Safety, Tolerability and Preliminary Effects of Oral BEL-X-HG in Patients With Advanced Refractory Solid Malignancies
Sponsor: A2 Healthcare Taiwan Corporation
Terminated
In the light of the on-going COVID-19 pandemic and the resulted difficulty in patient recruitment.
Listed as NCT03256331, this PHASE1 trial focuses on Advanced Solid Tumors and remains terminated or withdrawn. Sponsored by A2 Healthcare Taiwan Corporation, it has been updated 12 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2025 — Dec 2025 [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1
▶ Show 7 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE1
-
Jul 2020 — Nov 2020 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Apr 2020 — Jul 2020 [monthly]
Recruiting PHASE1
Status: Unknown Status → Recruiting
-
Mar 2020 — Apr 2020 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jun 2018 — Mar 2020 [monthly]
Recruiting PHASE1
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Jun 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- A2 Healthcare Taiwan Corporation
- Belx Bio-Pharmaceutical (Taiwan) Corporation
For direct contact, visit the study record on ClinicalTrials.gov .